File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2
  • Basic View
  • Metadata View
  • XML View
TitleMicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2
 
AuthorsLiang, L2
Wong, CM1
Ying, Q2
Fan, DNY1
Huang, S2
Ding, J2
Yao, J2
Yan, M2
Li, J2
Yao, M2
Ng, IOL1
He, X2
 
Issue Date2010
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
CitationHepatology, 2010, v. 52 n. 5, p. 1731-1740 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.23904
 
AbstractMicroRNAs (miRNAs) are small, noncoding RNAs that can act as oncogenes or tumor suppressors in human cancer. Our previous study showed that miR-125b was a prognostic indicator for patients with hepatocellular carcinoma (HCC), but its functions and exact mechanisms in hepatic carcinogenesis are still unknown. Here we demonstrate that miR-125b suppressed HCC cell growth in vitro and in vivo. Moreover, miR-125b increased p21Cip1/Waf1 expression and arrested cell cycle at G 1 to S transition. In addition, miR-125b inhibited HCC cell migration and invasion. Further studies revealed that LIN28B was a downstream target of miR-125b in HCC cells as miR-125b bound directly to the 3 untranslated region of LIN28B, thus reducing both the messenger RNA and protein levels of LIN28B. Silencing of LIN28B recapitulated the effects of miR-125b overexpression, whereas enforced expression of LIN28B reversed the suppressive effects of miR-125b. Conclusion: These findings indicate that miR-125b exerts tumor-suppressive effects in hepatic carcinogenesis through the suppression of oncogene LIN28B expression and suggest a therapeutic application of miR-125b in HCC. © 2010 American Association for the Study of Liver Diseases.
 
ISSN0270-9139
2013 Impact Factor: 11.190
 
DOIhttp://dx.doi.org/10.1002/hep.23904
 
ISI Accession Number IDWOS:000283764800023
Funding AgencyGrant Number
Ministry of Health of China2008ZX10002-017
Science & Technology Commission of Shanghai Municipality07DJ14006
Ministry of Human Resources and Social Security of China2007-170
Funding Information:

Supported by grants from The Ministry of Health of China (2008ZX10002-017), the Science & Technology Commission of Shanghai Municipality (07DJ14006), and the Ministry of Human Resources and Social Security of China (2007-170).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLiang, L
 
dc.contributor.authorWong, CM
 
dc.contributor.authorYing, Q
 
dc.contributor.authorFan, DNY
 
dc.contributor.authorHuang, S
 
dc.contributor.authorDing, J
 
dc.contributor.authorYao, J
 
dc.contributor.authorYan, M
 
dc.contributor.authorLi, J
 
dc.contributor.authorYao, M
 
dc.contributor.authorNg, IOL
 
dc.contributor.authorHe, X
 
dc.date.accessioned2011-08-26T14:29:41Z
 
dc.date.available2011-08-26T14:29:41Z
 
dc.date.issued2010
 
dc.description.abstractMicroRNAs (miRNAs) are small, noncoding RNAs that can act as oncogenes or tumor suppressors in human cancer. Our previous study showed that miR-125b was a prognostic indicator for patients with hepatocellular carcinoma (HCC), but its functions and exact mechanisms in hepatic carcinogenesis are still unknown. Here we demonstrate that miR-125b suppressed HCC cell growth in vitro and in vivo. Moreover, miR-125b increased p21Cip1/Waf1 expression and arrested cell cycle at G 1 to S transition. In addition, miR-125b inhibited HCC cell migration and invasion. Further studies revealed that LIN28B was a downstream target of miR-125b in HCC cells as miR-125b bound directly to the 3 untranslated region of LIN28B, thus reducing both the messenger RNA and protein levels of LIN28B. Silencing of LIN28B recapitulated the effects of miR-125b overexpression, whereas enforced expression of LIN28B reversed the suppressive effects of miR-125b. Conclusion: These findings indicate that miR-125b exerts tumor-suppressive effects in hepatic carcinogenesis through the suppression of oncogene LIN28B expression and suggest a therapeutic application of miR-125b in HCC. © 2010 American Association for the Study of Liver Diseases.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationHepatology, 2010, v. 52 n. 5, p. 1731-1740 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.23904
 
dc.identifier.citeulike8799928
 
dc.identifier.doihttp://dx.doi.org/10.1002/hep.23904
 
dc.identifier.epage1740
 
dc.identifier.hkuros190839
 
dc.identifier.isiWOS:000283764800023
Funding AgencyGrant Number
Ministry of Health of China2008ZX10002-017
Science & Technology Commission of Shanghai Municipality07DJ14006
Ministry of Human Resources and Social Security of China2007-170
Funding Information:

Supported by grants from The Ministry of Health of China (2008ZX10002-017), the Science & Technology Commission of Shanghai Municipality (07DJ14006), and the Ministry of Human Resources and Social Security of China (2007-170).

 
dc.identifier.issn0270-9139
2013 Impact Factor: 11.190
 
dc.identifier.issue5
 
dc.identifier.pmid20827722
 
dc.identifier.scopuseid_2-s2.0-78049521995
 
dc.identifier.spage1731
 
dc.identifier.urihttp://hdl.handle.net/10722/137627
 
dc.identifier.volume52
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshCell Cycle - drug effects
 
dc.subject.meshCell Division - drug effects
 
dc.subject.meshDNA-Binding Proteins - antagonists and inhibitors - drug effects
 
dc.subject.meshLiver Neoplasms - genetics - pathology
 
dc.subject.meshMicroRNAs - genetics - pharmacology
 
dc.titleMicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Liang, L</contributor.author>
<contributor.author>Wong, CM</contributor.author>
<contributor.author>Ying, Q</contributor.author>
<contributor.author>Fan, DNY</contributor.author>
<contributor.author>Huang, S</contributor.author>
<contributor.author>Ding, J</contributor.author>
<contributor.author>Yao, J</contributor.author>
<contributor.author>Yan, M</contributor.author>
<contributor.author>Li, J</contributor.author>
<contributor.author>Yao, M</contributor.author>
<contributor.author>Ng, IOL</contributor.author>
<contributor.author>He, X</contributor.author>
<date.accessioned>2011-08-26T14:29:41Z</date.accessioned>
<date.available>2011-08-26T14:29:41Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Hepatology, 2010, v. 52 n. 5, p. 1731-1740</identifier.citation>
<identifier.issn>0270-9139</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137627</identifier.uri>
<description.abstract>MicroRNAs (miRNAs) are small, noncoding RNAs that can act as oncogenes or tumor suppressors in human cancer. Our previous study showed that miR-125b was a prognostic indicator for patients with hepatocellular carcinoma (HCC), but its functions and exact mechanisms in hepatic carcinogenesis are still unknown. Here we demonstrate that miR-125b suppressed HCC cell growth in vitro and in vivo. Moreover, miR-125b increased p21Cip1/Waf1 expression and arrested cell cycle at G 1 to S transition. In addition, miR-125b inhibited HCC cell migration and invasion. Further studies revealed that LIN28B was a downstream target of miR-125b in HCC cells as miR-125b bound directly to the 3 untranslated region of LIN28B, thus reducing both the messenger RNA and protein levels of LIN28B. Silencing of LIN28B recapitulated the effects of miR-125b overexpression, whereas enforced expression of LIN28B reversed the suppressive effects of miR-125b. Conclusion: These findings indicate that miR-125b exerts tumor-suppressive effects in hepatic carcinogenesis through the suppression of oncogene LIN28B expression and suggest a therapeutic application of miR-125b in HCC. &#169; 2010 American Association for the Study of Liver Diseases.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher>
<relation.ispartof>Hepatology</relation.ispartof>
<rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject.mesh>Cell Cycle - drug effects</subject.mesh>
<subject.mesh>Cell Division - drug effects</subject.mesh>
<subject.mesh>DNA-Binding Proteins - antagonists and inhibitors - drug effects</subject.mesh>
<subject.mesh>Liver Neoplasms - genetics - pathology</subject.mesh>
<subject.mesh>MicroRNAs - genetics - pharmacology</subject.mesh>
<title>MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2</title>
<type>Article</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1002/hep.23904</identifier.doi>
<identifier.pmid>20827722</identifier.pmid>
<identifier.scopus>eid_2-s2.0-78049521995</identifier.scopus>
<identifier.hkuros>190839</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-78049521995&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>52</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>1731</identifier.spage>
<identifier.epage>1740</identifier.epage>
<identifier.isi>WOS:000283764800023</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.citeulike>8799928</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/137627/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Shanghai Jiao Tong University School of Medicine